United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

The Food and Drug Administration could approve the Pfizer and BioNTech Covid-19 vaccine on Monday, The New York Times reported.

Full approval for Pfizer Covid vaccine could come from FDA Monday, report says

The new licensing timeline is speedier than originally expected, the outlet reported.

The FDA hopes to fully approve the Pfizer vaccine on Monday, The New York Times reported

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis (JIA) and juvenile psoriatic arthritis (PsA) in patients two years of age and older who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (DMARDs). Two formulations were approved, a tablet and a new oral solution (weight-based dosing). XELJANZ is th

XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis

Apple

AbbVie

Anthem

Franklin Resources

Cisco Systems

Chevron

Home Depot

Johnson & Johnson

Lowe's

Altria

Microsoft

AT&T

T. Rowe Price Group

Texas Instruments

Wells Fargo

Xcel Energy

This is a quarterly review of DivGro, my portfolio of dividend growth stocks. I write these reviews to summarize investment decisions and to share portfolio statistics. The article includes charts showing DivGro's composition and how positions contribute to projected annual dividend income.

Quarterly Review Of DivGro: Q2-2021

Virtus LifeSci Biotech Clinical Trials ETF

Cerevel Therapeutics Holdings Inc

CM Life Sciences II Inc - Unit

Loncar Cancer Immunotherapy ETF

iShares Evolved U.S. Innovative Healthcare ETF

Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new fund directed at pharmaceutical, biotechnology and medical device companies, reported Endpoints News.

Should Investors Follow Private Equity into Life Sciences?

Moderna

In order to provide better protection to the American people from rising COVID-19 cases due to the surge of the Delta variant, U.S. health officials are recommending use of a booster dose for individuals starting this fall.

US Set to Receive COVID-19 Vaccine Booster Dose Next Month

ARK Genomic Revolution Multi-Sector ETF

One ARK Invest exchange-traded fund run by ETF star Cathie Wood bought over 150,000 shares of Pfizer Inc.

Cathie Wood's ARK Invest Buys Over 150,000 Shares of This COVID-19 Vaccine Supplier

The researchers found that fully vaccinated people carry just as much virus as unvaccinated people and warned that herd immunity for Covid-19 may be “unachievable” if they can also spread the disease as easily.

Covid Vaccines Less Effective Against Delta Variant—And Pfizer's Effectiveness Wanes Rapidly—Large Study Finds

DocuSign

Genius Sports

Palantir Technologies

Cathie Wood-led Ark Invest on Wednesday further increased her bets on Palantir Technologies Inc (NYSE:PLTR) on a day shares of the Peter Thiel-co-founded data analytics company extended gains. The popular money managing firm snapped up 93,189 shares — estimated to be worth $2.36 million — in Palantir on Wednesday.

Palantir, Pfizer, Square, Genius Sports, Docusign — Stocks Cathie Wood's Ark Bought Or Sold On Wednesday

Shares of Pfizer Inc.  traded today at $51.76, eclipsing its 52-week high. This new high was reached on approximately average trading volume as 31.6 million shares traded hands, while the average 30-day volume is approximately 32.7 million shares.

Pfizer Inc.: 52-Week High Recently Eclipsed (PFE)

Pfizer cleared a massive resistance level last week when it surged above its record high of $47.39 reached in 1999.

Pfizer extends 5-day gain to record territory as US recommends COVID-19 booster shot

Pfizer Inc. (NYSE:PFE) shares are trading higher Wednesday after an Israeli health care provider said a third dose of the vaccine was found to be 86% effective in those aged over 60 years old. Pfizer was up 1.9% at $51.40 at publication time.

Pfizer Stock Moves Higher Again...What's Next?

Health officials with the Biden administration say another shot is needed to maximize protection.

US to start offering Pfizer, Moderna booster shots for COVID-19 in September

Eli Lilly

Novo Nordisk

Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

3 Big Drug/Biotech Outperformers Worth Keeping an Eye On

Impurity concerns have prompted Pfizer Inc (NYSE: PFE) to pull another four Chantix lots in the U.S., bringing up to 16 batches of its total recall.  The latest action covers a quartet of 0.5/1-mg tablets, and as earlier Chantix recalls, this too stems from impurities discovered in the drugs that are above Pfizer's approved daily limit.

Pfizer Pulls Out Additional Lots Of It Anti-Smoking Pill

Pfizer (PFE)/BioNTech's (BNTX) booster dose of COVID-19 vaccine elicited antibody levels that were much higher than that seen after the two-dose primary schedule.

Pfizer (PFE)/BioNTech Give First COVID Jab Booster Data to FDA

Shares of Pfizer inc. ( PFE , Financial) have gained more than 16% since reporting earnings results late last month.

Pfizer: The Rally Is Far From Finished

Why Pfizer and Moderna Won't Make As Much Extra Money From U.S. Booster Doses As You Might Think

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the pricing of a sustainability bond of $1,000,000,000 in aggregate principal amount of 1.750% senior notes due 2031. The closing of the offering is expected to occur on August 18, 2021, subject to satisfaction of customary closing conditions. Pfizer intends to use the net proceeds to finance or refinance, in whole or in part as follows: research and development expenses related to COVID-19 vaccine research and development, capi

Pfizer Prices $1.0 Billion Sustainability Bond

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have submitted Phase 1 data to the FDA to support the evaluation of their COVID-19 booster dose for future licensure.  The data also will be submitted to the European Medicines Agency (EMA) and other regulatory authorities in the coming weeks.

Do You Need A COVID-19 Booster Dose? Pfizer-BioNTech Submit Initial Data To Support Idea

Pfizer's (PFE) tick-borne encephalitis vaccine that is already approved in Europe and other countries gains FDA approval.

Pfizer's (PFE) Tick-Borne Encephalitis Vaccine Gets FDA Nod

Pfizer and BioNTech said they have submitted early-stage clinical trial data to the FDA as part of their application seeking U.S. OK of a Covid booster shot.

Pfizer submits data to FDA for authorization of Covid vaccine booster shot for general population

Pfizer Inc. PFE, +0.33% and partner BioNTech SE BNTX, -10.29% announced Monday that data from a Phase 1 study has been submitted to the U.S. Food and Drug Administration, for the evaluation of a third, booster dose of their COVID-19 vaccine. The companies said they will also submit the data to the European Union's version of the FDA, the European Medicines Agency, as well as other regulatory authorities, in the coming weeks.

Pfizer, BioNTech submit trial data on COVID-19 booster shot to FDA

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they have submitted Phase 1 data to the U.S. Food and Drug Administration (FDA) to support the evaluation of a third, or booster, dose of the companies' COVID-19 vaccine (BNT162b2) for future licensure. These data also will be submitted to the European Medicines Agency (EMA) and other regulatory authorities in the coming weeks. “Vaccination is our most effective means of preve

Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine

The FDA approved Pfizer Inc's (NYSE:PFE) TICOVAC (tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals one year of age and older. TICOVAC was developed using a master 'seed' virus similar to the TBE virus found in nature.

News for Pfizer Stock (PFE)